Cernostics is a diagnostics company focused on delivering next generation cancer diagnostics and prognostics through a unique approach to tissue analysis.

Most current diagnostic approaches offer a limited view of cancer because they fail to evaluate the tumor as a system composed of multiple interacting cell types.

Cernostics takes a tissue systems biology approach to anatomic pathology. Its patent-protected technology platform, TissueCypher, uniquely analyzes whole slide digital images with multiplexed fluorescence, providing greater information and accuracy than traditional subjective tissue diagnostics. Learn more about our technology platform [www.cernostics.com] and how it will change the future of cancer diagnostics.

Source: https://www.linkedin.com/company/cernostics-inc/

Company Size: 11-50 employees

Cernostics

Login